Develops genetic medicines for rare diseases and genetic disorders, focusing on gene therapies and RNA-based technologies.
Korro Bio, Inc. is a pioneering biopharmaceutical firm specializing in the discovery, development, and commercialization of genetic medicines through RNA editing. Headquartered in Cambridge, Massachusetts, the company focuses on addressing rare and prevalent diseases, primarily in the United States. Central to Korro Bio's innovative approach is its RNA editing platform, OPERA, which enables the creation of distinct RNA editing product candidates tailored to specific therapeutic needs.
At the forefront of Korro Bio's pipeline is KRRO-110, its lead product candidate currently undergoing preclinical trials. KRRO-110 holds promise for treating Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder characterized by reduced levels of a vital protein in the blood.
Beyond KRRO-110, Korro Bio is advancing programs targeting a spectrum of conditions including Parkinson's disease, Amyotrophic lateral sclerosis (ALS), severe alcohol-associated hepatitis, and various subsets of pain. By leveraging its expertise in RNA editing, Korro Bio aims to offer innovative therapeutic solutions that address significant unmet medical needs across diverse patient populations. Founded in 2018, the company remains dedicated to transforming the landscape of genetic medicine through cutting-edge research and development efforts.